Mostrar el registro sencillo del ítem

Antimicrobial development in the era of emerging resistance

dc.contributor.authorSorlozano Puerto, Antonio 
dc.contributor.authorCarrasco, Cristina
dc.contributor.authorCabeza, José
dc.contributor.authorVillegas Martínez, Enrique
dc.contributor.authorGutiérrez Fernández, José 
dc.date.accessioned2024-04-11T11:56:19Z
dc.date.available2024-04-11T11:56:19Z
dc.date.issued2009-07
dc.identifier.citationSorlozano A, Carrasco C, Cabeza J, Villegas E, Gutierrez J. Antimicrobial development in the era of emerging resistance. Mini Rev Med Chem. 2009 Jul;9(8):938-55. DOI:10.2174/138955709788681564es_ES
dc.identifier.urihttps://hdl.handle.net/10481/90659
dc.description.abstractAntibiotics currently under study by the Food and Drugs Administration include: faropenem (for treatment of sinusitis, bronchitis, and community-acquired pneumonia), dalbavancin (for catheter infections), telavancin (for treatment of nosocomial pneumonia), oritavancin (for bacteremia), ceftobiprole and iclaprim (for pneumonias). Moreover, all of them would be useful for skin and soft tissue infections.es_ES
dc.language.isoenges_ES
dc.publisherBentham Science Publisherses_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectFaropenemes_ES
dc.subjectDalbavancines_ES
dc.subjectTelavancines_ES
dc.subjectOritavancines_ES
dc.subjectCeftobiprolees_ES
dc.subjectIclaprimes_ES
dc.titleAntimicrobial development in the era of emerging resistancees_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.2174/138955709788681564
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

[PDF]
Nombre:
Antimicrobial_Development_in_t ...
Tamaño:
348.1Kb
Formato:
PDF

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional